TGen to Participate in DoD Program Studying Pharmacogenomics of Breast Cancer | GenomeWeb
NEW YORK (GenomeWeb News) – The Translational Genomics Reserach Institute will play a "primary" role in a $10.7-million Department of Defense breast cancer research program, the nonprofit said yesterday.
 
The multi-institutional, five-year research program is led by Philadelphia’s Fox Chase Cancer Center. The grant focuses on developing a new treatment model for breast cancer to reverse resistance to anti-estrogen therapy.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.